Not exact matches
Our team was instrumental in the development of
talimogene laherparepvec, the first in human oncolytic
virus therapy for patients with melanoma.
Called
talimogene laherparepvec (Imlygic ™), and made by Amgen, the immunotherapy is an oncolytic
virus therapy.
In October 2015 — around the same time that the FDA was granting several approvals and indication extensions to checkpoint inhibitors — the agency approved the oncolytic
virus (herpes simplex
virus 1)-- derived
therapy talimogene laherparepvec (T - VEC) for the treatment of melanoma lesions in the skin and lymph nodes.